For the quarter ending 2026-03-31, DYAI had -$697,771 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,954,683 | -1,567,263 | -1,976,012 | -3,821,353 |
| Stock-based compensation expense | 139,299 | 192,339 | 172,352 | 565,492 |
| Amortization of held-to-maturity securities, net | -3,390 | -3,419 | -4,754 | -15,996 |
| Gain from the sale of investment in alphazyme | - | - | - | 0 |
| Amortization of debt issuance costs | 7,381 | 12,593 | 12,310 | 23,794 |
| Foreign currency exchange (gain) loss, net | 9,591 | -10,977 | -12,754 | -23,170 |
| Interest receivable | -22,706 | 1,012 | -619 | 10,488 |
| Accounts receivable | -89,375 | 173,662 | 201,442 | 471,860 |
| Prepaid expenses and other current assets | -44,908 | -120,880 | 254,966 | -218,050 |
| Operating lease assets and liabilities | -442 | -440 | -144 | 11 |
| Accounts payable | 222,697 | -367,095 | 457,466 | 224,080 |
| Accrued expenses | 98,688 | -404,390 | 442,513 | 191,009 |
| Accrued interest | - | 0 | -20,000 | 0 |
| Accrued interest - related party | - | 16,667 | 3,333 | -5,373 |
| Deferred research and development obligation | -620,282 | 393,714 | -496,393 | 999,718 |
| Net cash used in operating activities | -1,963,334 | -1,770,111 | -1,852,364 | -2,079,746 |
| Proceeds from the sale of investment in alphazyme | - | - | - | 0 |
| Purchases of held-to-maturity investment securities | 566,547 | 861,424 | 530,568 | 4,560,278 |
| Proceeds from maturities of investment securities | 1,832,743 | 1,329,583 | 624,010 | 4,080,762 |
| Net cash provided by investing activities | 1,266,196 | 468,159 | 93,442 | -479,516 |
| Proceeds from public offering, net of offering costs | - | -1 | 4,940,696 | - |
| Proceeds from exercise of options | - | 0 | 0 | 24,249 |
| Proceeds from issuance of convertible notes, net of issuance costs - related party | - | - | - | 0 |
| Proceeds from issuance of convertible notes, net of issuance costs | - | - | - | 0 |
| Net cash provided by financing activities | - | -1 | 4,940,696 | 24,249 |
| Effect of exchange rate changes on cash | -633 | -336 | -416 | 2,693 |
| Net decrease in cash, cash equivalents, and restricted cash | -697,771 | -1,302,289 | 3,181,358 | -2,532,320 |
| Cash, cash equivalents, and restricted cash at beginning of period | 5,853,499 | 7,155,788 | 6,506,750 | - |
| Cash, cash equivalents, and restricted cash at end of period | 5,155,728 | 5,853,499 | 7,155,788 | - |
DYADIC INTERNATIONAL INC (DYAI)
DYADIC INTERNATIONAL INC (DYAI)